Investor Relations
News Release Details
Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
|
|
Title: |
Adoptive |
Date: |
|
Presenter: |
Dr. Simon |
Abstract number: |
1179 |
* This will be a virtual event in 2020 due to the COVID-19 pandemic |
|
ASCO20 Virtual Scientific Program |
|
Title: |
Intratumoral use of self-delivering RNAi to reprogram the tumor microenvironment and boost the antitumor response |
Date: |
|
Presenter: |
Dr. Gerrit Dispersyn |
Abstract number: |
e15206 |
* This will be a virtual event in 2020 due to the COVID-19 pandemic |
|
|
|
Title: |
Intratumoral delivery of mPH-804 (TIGIT targeting INTASYL compound) inhibits tumor growth and confers an inflammatory tumor microenvironment |
Date: |
|
Session Title: |
Immune Checkpoints 2 |
Presenter: |
Dr. |
Abstract number: |
5745 |
* This will be the second of two AACR virtual annual meeting events being held in 2020 due to the COVID-19 pandemic |
|
|
|
Date: |
|
Time: |
|
Presenter: |
Dr. Gerrit Dispersyn |
Location: |
Free registration for the event is available (click here) or visit the Phio website (click here) |
* This will be a virtual event in 2020 due to the COVID-19 pandemic |
The poster presentations and the corporate presentation will be made available under the "Investors – Events and Presentations" section of the Company's website approximately one hour after each event.
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the results of our preclinical studies, future of our business, future plans and strategies, projections, anticipated events and trends, the economy, the impact to our business and operations by the recent coronavirus outbreak, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the
Contact
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
arr@lifesciadvisors.com
View original content:http://www.prnewswire.com/news-releases/phio-to-present-at-upcoming-medical-meetings-and-investor-conference-in-spring-2020-301051461.html
SOURCE